Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases

Intracerebral hemorrhage (ICH) is characterized by parenchymal hematoma formation with surrounding inflammation. Matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of neurological diseases defined by inflammation and cell death. To investigate the expression profile and pathogenic aspects of MMPs in ICH, we examined MMP expression in vivo using a collagenase‐induced rat model of ICH. ICH increased brain MMP‐2, ‐3, ‐7, and ‐9 mRNA levels relative to sham‐injected (control) animals in the vicinity of the hematoma, but MMP‐12 (macrophage metalloelastase) was the most highly induced MMP (>80‐fold). Immunohistochemistry showed MMP‐12 to be localized in activated monocytoid cells surrounding the hematoma. In vitro studies showed that thrombin, released during ICH, induced MMP‐12 expression in monocytoid cells, which was reduced by minocycline application. Similarly, in vivo minocycline treatment significantly reduced MMP‐12 levels in brain. Neuropathological studies disclosed marked glial activation and apoptosis after ICH that was reduced by minocycline treatment. Neurobehavioral outcomes also were improved with minocycline treatment compared with untreated ICH controls. Thus, select MMPs exhibit increased expression after ICH, whereas minocycline is neuroprotective after ICH by suppressing monocytoid cell activation and downregulating MMP‐12 expression.Ann Neurol 2003;53:731–742

[1]  J. Serena,et al.  Plasma Metalloproteinase-9 Concentration Predicts Hemorrhagic Transformation in Acute Ischemic Stroke , 2003, Stroke.

[2]  V. Yong,et al.  Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. , 2002, Brain : a journal of neurology.

[3]  Betty Y. S. Kim,et al.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.

[4]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[5]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats , 2002, Stroke.

[6]  C. Kase,et al.  Molecular signatures of brain injury after intracerebral hemorrhage , 2002, Neurology.

[7]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[8]  I. Duncan,et al.  Inhibition of autoimmune encephalomyelitis by a tetracycline , 2002, Annals of neurology.

[9]  Taku Sugawara,et al.  Matrix Metalloproteinase Inhibition Prevents Oxidative Stress-Associated Blood–Brain Barrier Disruption after Transient Focal Cerebral Ischemia , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  J. Arenillas,et al.  Matrix Metalloproteinase Expression Is Related to Hemorrhagic Transformation After Cardioembolic Stroke , 2001, Stroke.

[11]  Yoon Lee,et al.  Tumor Necrosis Factor Receptor Superfamily 14 Is Involved in Atherogenesis by Inducing Proinflammatory Cytokines and Matrix Metalloproteinases , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[12]  S. Paul,et al.  Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons , 2001, Neuroscience Letters.

[13]  M. D. Del Bigio,et al.  Acute Tissue Damage After Injections of Thrombin and Plasmin into Rat Striatum , 2001, Stroke.

[14]  W. Le,et al.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum , 2001, Brain Research.

[15]  V. Wee Yong,et al.  Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.

[16]  James Peeling,et al.  Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage , 2001, Annals of neurology.

[17]  C. Power,et al.  Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis , 2001, Annals of neurology.

[18]  J. Tonn,et al.  Production of MMPs in Human Cerebral Endothelial Cells and Their Role in Shedding Adhesion Molecules , 2001, Journal of neuropathology and experimental neurology.

[19]  D. Corbett,et al.  HIV‐1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors , 2001, Annals of neurology.

[20]  M. D. Del Bigio,et al.  Antisense Oligodeoxynucleotide Inhibition of Tumor Necrosis Factor-&agr; Expression Is Neuroprotective After Intracerebral Hemorrhage , 2001, Stroke.

[21]  P. Lapchak,et al.  Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic Stroke , 2000, Stroke.

[22]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[23]  R. Keep,et al.  Acute inflammatory reaction following experimental intracerebral hemorrhage in rat , 2000, Brain Research.

[24]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[25]  T. Watanabe,et al.  Induction and regulation of matrix metalloproteinase-12 by cytokines and CD40 signaling in monocyte/macrophages. , 2000, Biochemical and biophysical research communications.

[26]  B. Fingleton,et al.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.

[27]  P. Chan,et al.  A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Z. Werb,et al.  Matrix Metalloproteinase-9/Gelatinase B Is Required for Process Outgrowth by Oligodendrocytes , 1999, The Journal of Neuroscience.

[29]  M. Fujimura,et al.  Early appearance of activated matrix metalloproteinase-9 and blood–brain barrier disruption in mice after focal cerebral ischemia and reperfusion , 1999, Brain Research.

[30]  J. Koziol,et al.  Matrix Metalloproteinases Increase Very Early during Experimental Focal Cerebral Ischemia , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  B. Stricker,et al.  Minocycline and lupuslike syndrome in acne patients. , 1999, Archives of internal medicine.

[32]  T. Hökfelt,et al.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Rosenberg,et al.  Matrix Metalloproteinases in Cerebrovascular Disease , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  V. Perry,et al.  Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS , 1998, Journal of Neuroimmunology.

[35]  F. Barone,et al.  Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. , 1998, Stroke.

[36]  Dale Corbett,et al.  The problem of assessing effective neuroprotection in experimental cerebral ischemia , 1998, Progress in Neurobiology.

[37]  S. Strickland,et al.  Neuronal Death in the Hippocampus Is Promoted by Plasmin-Catalyzed Degradation of Laminin , 1997, Cell.

[38]  A. Clark,et al.  Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia , 1997, Neuroscience Letters.

[39]  S. Knowles,et al.  Comparative safety of tetracycline, minocycline, and doxycycline. , 1997, Archives of dermatology.

[40]  J. Roujeau,et al.  Benefit-risk assessment of acne therapies , 1997, The Lancet.

[41]  G. Rosenberg,et al.  Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat , 1997, Neurology.

[42]  R. Buist,et al.  Experimental intracerebral hemorrhage in rats. Magnetic resonance imaging and histopathological correlates. , 1996, Stroke.

[43]  Y. Imai,et al.  A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. , 1996, Biochemical and biophysical research communications.

[44]  D. Corbett,et al.  Delayed postischemic hypothermia: a six month survival study using behavioral and histological assessments of neuroprotection. , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[45]  John Calvin Reed,et al.  Anchorage dependence, integrins, and apoptosis , 1994, Cell.

[46]  T. Crawford,et al.  Cerebral white matter changes in acquired immunodeficiency syndrome dementia: Alterations of the blood‐brain barrier , 1993, Annals of neurology.

[47]  L. Liotta,et al.  TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase , 1992, Brain Research.

[48]  R. Béliveau,et al.  Expression of matrix metalloproteinases and their inhibitors in human brain tumors , 2004, Clinical & Experimental Metastasis.

[49]  P. Lapchak.  Hemorrhagic transformation following ischemic stroke: Significance, causes, and relationship to therapy and treatment , 2002, Current neurology and neuroscience reports.

[50]  Raul G Nogueira,et al.  Spontaneous intracerebral hemorrhage. , 1992, Neurosurgery clinics of North America.